| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Pediatrics and Biochemistry and Molecular Biology and 2 Pathology, Keck School of Medicine, University of Southern California and The Saban Research Institute, Childrens Hospital Los Angeles, Los Angeles, California; 3 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 4 Department of Pharmacology, Agouron Pharmaceuticals, Inc., a Pfizer Company, La Jolla, California; and 5 Department of Anatomy and 6 Cancer Research Institute and Department of Pathology, University of California San Francisco, San Francisco, California
Advanced stages of neuroblastoma show increased expression of matrix metalloproteinases MMP-2 and MMP-9 (Y. Sugiura et al., Cancer Res., 58: 22092216, 1998) that have been implicated in many steps of tumor progression, suggesting that they play a contributory role. Using pharmacological and genetic approaches, we have examined the role of these MMPs in progression of SK-N-BE (2).10 human neuroblastoma tumors orthotopically xenotransplanted into immunodeficient mice. Mice treated with Prinomastat, a synthetic inhibitor of MMPs, showed an inhibition of tumor cell proliferation in implanted tumors and a prolonged survival (50 versus 39 days in control group, P < 0.035). Treatment with Prinomastat did not affect formation of liver metastases (P = 0.52) but inhibited intravascular colonization by the tumor cells in the lung by 73.8% (P = 0.03) and angiogenesis in both primary tumors and experimental liver metastases. The primary tumors from Prinomastat-treated mice showed a 39.3% reduction in endothelial area detected by PECAM/CD31 staining in tumor sections (P < 0.001), primarily due to the presence of smaller vessels (P = 0.004). MMP-2 is expressed by neuroblastoma tumor cells and stromal cells, whereas MMP-9 is exclusively expressed by stromal cells, particularly vascular cells. To examine the contribution of MMP-9 to tumor angiogenesis, we generated RAG1/MMP-9 double-deficient mice. We observed a significant inhibition of angiogenesis in the immunodeficient RAG1/MMP-9 double-deficient mice orthotopically implanted with tumor cells (P = 0.043) or implanted s.c. with a mixture of tumor cells and Matrigel (P < 0.001). Using an FITC-labeled lectin, we demonstrated an inhibition in the architecture of the tumor vasculature in MMP-9-deficient mice, resulting in fewer and smaller blood vessels. These changes were associated with a 48% decrease in pericytes present along microvessels. Taken together, the data demonstrate that in neuroblastoma, stromally derived MMP-9 contributes to angiogenesis by promoting blood vessel morphogenesis and pericyte recruitment.
This article has been cited by other articles:
![]() |
M. D. Martin, K. J. Carter, S. R. Jean-Philippe, M. Chang, S. Mobashery, S. Thiolloy, C. C. Lynch, L. M. Matrisian, and B. Fingleton Effect of Ablation or Inhibition of Stromal Matrix Metalloproteinase-9 on Lung Metastasis in a Breast Cancer Model Is Dependent on Genetic Background Cancer Res., August 1, 2008; 68(15): 6251 - 6259. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Arnold, E. Mira, S. Muneer, G. Korpanty, A. W. Beck, S. E. Holloway, S. Manes, and R. A. Brekken Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC Experimental Biology and Medicine, July 1, 2008; 233(7): 860 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W.M. van Hinsbergh and P. Koolwijk Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead Cardiovasc Res, May 1, 2008; 78(2): 203 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gerg, C. Kopitz, S. Schaten, A. Tschukes, C. Kahlert, M. Stangl, C. W. Hann von Weyhern, B. L.D.M. Brucher, D. R. Edwards, K. Brand, et al. Distinct Functionality of Tumor Cell-Derived Gelatinases during Formation of Liver Metastases Mol. Cancer Res., March 1, 2008; 6(3): 341 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors Cancer Res., February 15, 2008; 68(4): 1170 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Nangia-Makker, T. Raz, L. Tait, V. Hogan, R. Fridman, and A. Raz Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast Cancers Cancer Res., December 15, 2007; 67(24): 11760 - 11768. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ivanciu, R. D. Gerard, H. Tang, F. Lupu, and C. Lupu Adenovirus-Mediated Expression of Tissue Factor Pathway Inhibitor-2 Inhibits Endothelial Cell Migration and Angiogenesis Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 310 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen Monocyte/macrophage infiltration in tumors: modulators of angiogenesis J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jost, A. R. Folgueras, F. Frerart, A. M. Pendas, S. Blacher, X. Houard, S. Berndt, C. Munaut, D. Cataldo, J. Alvarez, et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res., May 15, 2006; 66(10): 5234 - 5241. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Blavier, A. Lazaryev, F. Dorey, G. M. Shackleford, and Y. A. DeClerck Matrix metalloproteinases play an active role in wnt1-induced mammary tumorigenesis. Cancer Res., March 1, 2006; 66(5): 2691 - 2699. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zijlstra, M. Seandel, T. A. Kupriyanova, J. J. Partridge, M. A. Madsen, E. A. Hahn-Dantona, J. P. Quigley, and E. I. Deryugina Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells Blood, January 1, 2006; 107(1): 317 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Deryugina, A. Zijlstra, J. J. Partridge, T. A. Kupriyanova, M. A. Madsen, T. Papagiannakopoulos, and J. P. Quigley Unexpected Effect of Matrix Metalloproteinase Down-Regulation on Vascular Intravasation and Metastasis of Human Fibrosarcoma Cells Selected In vivo for High Rates of Dissemination Cancer Res., December 1, 2005; 65(23): 10959 - 10969. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hecht, J. H. Schulte, A. Eggert, J. Wilting, and L. Schweigerer The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness Carcinogenesis, December 1, 2005; 26(12): 2105 - 2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jodele, C. F. Chantrain, L. Blavier, C. Lutzko, G. M. Crooks, H. Shimada, L. M. Coussens, and Y. A. DeClerck The Contribution of Bone Marrow-Derived Cells to the Tumor Vasculature in Neuroblastoma Is Matrix Metalloproteinase-9 Dependent Cancer Res., April 15, 2005; 65(8): 3200 - 3208. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sohara, H. Shimada, C. Minkin, A. Erdreich-Epstein, J. A. Nolta, and Y. A. DeClerck Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer Cells Cancer Res., February 15, 2005; 65(4): 1129 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Cornet, C. Galant, Y. Eeckhout, P. J. Courtoy, E. Marbaix, and P. Henriet Regulation of Matrix Metalloproteinase-9/Gelatinase B Expression and Activation by Ovarian Steroids and LEFTY-A/Endometrial Bleeding-Associated Factor in the Human Endometrium J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1001 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrario, C. F. Chantrain, K. von Tiehl, S. Buckley, N. Rucker, D. R. Shalinsky, H. Shimada, Y. A. DeClerck, and C. J. Gomer The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model Cancer Res., April 1, 2004; 64(7): 2328 - 2332. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |